Tags

Type your tag names separated by a space and hit enter

[Strategies for vaccine development of COVID-19].
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25; 36(4):593-604.SW

Abstract

An epidemic of acute respiratory syndrome in humans, which appeared in Wuhan, China in December 2019, was caused by a novel coronavirus (SARS-CoV-2). This disease was named as "Coronavirus Disease 2019" (COVID-19). SARS-CoV-2 was first identified as an etiological pathogen of COVID-19, belonging to the species of severe acute respiratory syndrome-related coronaviruses (SARSr-CoV). The speed of both the geographical transmission and the sudden increase in numbers of cases is much faster than SARS and Middle East respiratory syndrome (MERS). COVID-19 is the first global pandemic caused by a coronavirus, which outbreaks in 211 countries/territories/areas. The vaccine against COVID-19, regarded as an effective prophylactic strategy for control and prevention, is being developed in about 90 institutions worldwide. The experiences and lessons encountered in the previous SARS and MERS vaccine research can be used for reference in the development of COVID-19 vaccine. The present paper hopes to provide some insights for COVID-19 vaccines researchers.

Authors+Show Affiliations

CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China. Chinese Academy of Sciences University, Beijing 100049, China.

Pub Type(s)

Journal Article
Review

Language

chi

PubMed ID

32347054

Citation

Yang, Limin, et al. "[Strategies for Vaccine Development of COVID-19]." Sheng Wu Gong Cheng Xue Bao = Chinese Journal of Biotechnology, vol. 36, no. 4, 2020, pp. 593-604.
Yang L, Tian D, Liu W. [Strategies for vaccine development of COVID-19]. Sheng Wu Gong Cheng Xue Bao. 2020;36(4):593-604.
Yang, L., Tian, D., & Liu, W. (2020). [Strategies for vaccine development of COVID-19]. Sheng Wu Gong Cheng Xue Bao = Chinese Journal of Biotechnology, 36(4), 593-604. https://doi.org/10.13345/j.cjb.200094
Yang L, Tian D, Liu W. [Strategies for Vaccine Development of COVID-19]. Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):593-604. PubMed PMID: 32347054.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Strategies for vaccine development of COVID-19]. AU - Yang,Limin, AU - Tian,Deyu, AU - Liu,Wenjun, PY - 2020/4/30/entrez PY - 2020/4/30/pubmed PY - 2020/5/2/medline KW - COVID-19 KW - antibody KW - antibody-dependent enhancement KW - mucosal immunization KW - vaccine SP - 593 EP - 604 JF - Sheng wu gong cheng xue bao = Chinese journal of biotechnology JO - Sheng Wu Gong Cheng Xue Bao VL - 36 IS - 4 N2 - An epidemic of acute respiratory syndrome in humans, which appeared in Wuhan, China in December 2019, was caused by a novel coronavirus (SARS-CoV-2). This disease was named as "Coronavirus Disease 2019" (COVID-19). SARS-CoV-2 was first identified as an etiological pathogen of COVID-19, belonging to the species of severe acute respiratory syndrome-related coronaviruses (SARSr-CoV). The speed of both the geographical transmission and the sudden increase in numbers of cases is much faster than SARS and Middle East respiratory syndrome (MERS). COVID-19 is the first global pandemic caused by a coronavirus, which outbreaks in 211 countries/territories/areas. The vaccine against COVID-19, regarded as an effective prophylactic strategy for control and prevention, is being developed in about 90 institutions worldwide. The experiences and lessons encountered in the previous SARS and MERS vaccine research can be used for reference in the development of COVID-19 vaccine. The present paper hopes to provide some insights for COVID-19 vaccines researchers. SN - 1872-2075 UR - https://www.unboundmedicine.com/medline/citation/32347054/[Strategies_for_vaccine_development_of_COVID_19]_ L2 - https://doi.org/10.13345/j.cjb.200094 DB - PRIME DP - Unbound Medicine ER -